

## Figure S4: Combining FAKi with RT leads to immune priming *in-vivo*

(A) Day 7 pancreas weight of KPC mice from Fig. 4A. Representative gross tissue images are depicted. n = at least 7 mice/group. (B) Day 14 pancreas weight of KPC-OG mice from Fig. 4I treated as depicted in Fig. 4A. n = at least 7 mice/group. (C) Waterfall plot of PDA.69 (KRAS<sup>G12D</sup>/p53<sup>R172H/+</sup>) syngeneic tumor-bearing mice treated as depicted in Fig. 4A evaluating tumor growth difference from day 0 to 5. n = 10 mice/group. (D) Waterfall plot of KRAS-INK orthotopic tumor-bearing mice treated as depicted in Fig. 4A evaluating tumor growth difference from day 0 to 7. n = 5-10 mice/group. (E) IHC analysis of CK19<sup>+</sup> tumor cells in KPC mice at day 14. n = at least 7 mice/group. (F) Tumor grade and representative H&E images of KPC mice at day 14. n = at least 7 mice/group. (G) Flow cytometry quantification of total CD8<sup>+</sup> T cells and percentage of CD44<sup>+</sup> CD8<sup>+</sup> T cells out of total CD8<sup>+</sup> T cells in KPC mice at day 14. n = at least 7 mice/group. (H) mIHC analysis of CD4<sup>+</sup> Foxp3<sup>+</sup> T regulatory cells in tissues from KPC mice at day 14. Representative CK19, CD4, and Foxp3 fused mIHC images are depicted. n = at least 5 mice/group. (I) Tumor growth kinetics of KP2 syngeneic tumor-bearing mice from Fig. 4L-M. n = 10 mice/group. (J) Day 40 tumor weight of KP2-OVA-GFP tumor bearing mice treated with RT ± FAKi ± αIFNAR1 blocking antibody. n = 10 mice/group.

All graphs depict mean +/- SEM. "\*" denotes p < 0.05 by two-tailed t-test or one-way ANOVA as appropriate. "ns" denotes not significant.